CytomX Therapeutics, Inc. (CTMX) AI-Powered Stock Analysis
See how CytomX Therapeutics, Inc. scores across key metrics like financial growth, valuation, and market position using AI-driven evaluation.
CTMX●NASDAQ
HealthcareBiotechnology
$2.94
$0.06(2.000%)
U.S. Market opens in 9h 42m
Advertisement
CytomX Therapeutics, Inc. (CTMX)
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full DisclaimerCytomX Therapeutics, Inc. (CTMX) Stock Overall Grade
CytomX Therapeutics, Inc.’s grade based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to CytomX Therapeutics, Inc.'s overall stock rating.
Forecast
BScore
60/100Financial Growth
AScore
80/100Fundamental Growth
DScore
33/100Key Ratios
C+Score
55/100Sector Comparison
B+Score
75/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
99/100Analyst Consensus
B+Score
75/100CytomX Therapeutics, Inc. (CTMX) AI-Powered Stock Analysis
This asset demonstrates Good performance with an overall Forecast Score of 60/100 (B), reflecting weak confidence in its potential. Financial Growth (80/100, A) and Fundamental Growth (33/100, D) highlight its stability, while Key Ratios (55/100, C+) and Sector Comparison (75/100, B+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (99/100, A+), it shows competitive strength. Analyst Consensus (75/100,B+) suggests High divergence in outlook.Component Analysis Explained
Understand the key factors behind each CytomX Therapeutics, Inc. stock grade, including financials, comparisons, and forecasts.